Kohjin Bio Co., Ltd. (TYO:177A)

Japan · Delayed Price · Currency is JPY

895.00

-3.00 (-0.33%)

Jul 16, 2026, 10:43 AM JST

-47.35% (1Y)

Market Cap	4.59B -48.5%
Revenue (ttm)	4.94B -5.1%
Net Income	251.00M -68.4%
EPS	49.10 -68.8%
Shares Out	5.11M
PE Ratio	18.29
Forward PE	n/a
Dividend	10.00 (1.14%)
Ex-Dividend Date	Mar 30, 2026

Volume	1,900
Open	898.00
Previous Close	898.00
Day's Range	883.00 - 898.00
52-Week Range	841.00 - 2,020.00
Beta	0.00
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 14, 2026

About Kohjin Bio

Kohjin Bio Co., Ltd. manufactures and sells of animal blood, sera, tissue culture media, media for microbiology testing, in vitro diagnostic agents, and cosmetics. The company offers tissue culture mediums for human cell culture, including human lymphocyte culture, hepatoblastoma-derived cell lines, adipose- derived stem cells, neural stem cells, fibroblast, vascular endothelial cells, and epidermal keratinocyte human cell cultures. It also provides industrial cell cultures for CHO, hybridomas, and insect cells; exosome production; cryopreserva... [Read more]

Industry Biotechnology

Sector Healthcare

Founded 1981

Employees 176

Stock Exchange Tokyo Stock Exchange

Ticker Symbol 177A

Full Company Profile

Financial Performance

In fiscal year 2026, Kohjin Bio's revenue was 4.94 billion, a decrease of -5.13% compared to the previous year's 5.21 billion. Earnings were 251.00 million, a decrease of -68.39%.

Financial Statements